Forest Laboratories Inc. disclosed in its latest annual report on Form 10-K filed with the U.S. Securities and Exchange Commission that in March 2011, the company entered into a Stipulation of Settlement to resolve two derivative actions brought against its…
Forest Laboratories Inc. disclosed in its latest annual report on Form 10-K filed with the U.S. Securities and Exchange Commission that the company received a subpoena dated April 20, 2011 from the Office of the U.S. Attorney for the District…
Forest Laboratories Inc. disclosed in its latest annual report on Form 10-K filed with the U.S. Securities and Exchange Commission that the company (FLI) and Forest Pharmaceuticals, Inc. (FPI) remain defendants in several actions regarding overcharging of Medicaid drug reimbursement…
Forest Laboratories Inc. (FLI) and Forest Pharmaceuticals, Inc. (FPI) are named as defendants in two similar actions pending in the Missouri Circuit Court, Twenty-Second Judicial Circuit, arising from nearly identical allegations as those contained in the federal actions.
The first action,…
Forest Laboratories Inc. disclosed in its latest annual report on Form 10-K filed with the U.S. Securities and Exchange Commission that Howard Solomon, the company’s Chairman, Chief Executive Officer and President, has received a notice from the Office of the…
Forest Laboratories Inc. continues to cooperate in an investigation of the U.S. Attorney’s Office for the District of Massachusetts related to its commercial relationship with Omnicare, Inc. (Omnicare), a long-term care pharmacy provider, the company disclosed in its latest annual…
Forest Laboratories, Inc. is named in 70 product liability lawsuits for the period ended June 30, 2008, according to the Company’s latest quarterly report filed with the Securities and Exchange Commission.
More than 40 of the lawsuits allege that Celexa…